Unveiling New Frontiers in Weight Management: Insights from Shawn Baier

In a recent interview, Nutritional Outlook sat down with Shawn Baier, Vice President of Business Development for TSI Group SupplySide East, to explore burgeoning opportunities within the weight management and energy sectors.

Baier shed light on the surging interest in GLP-1 receptor agonists like Ozempic, stressing the pivotal role of ingredient and supplement companies in confronting the associated challenges head-on.

According to Baier, the use of GLP-1 RAs often imposes severe restrictions on nutritional intake, akin to starvation. Baier emphasized how important it is for users to prioritize nutrient-dense, low-calorie foods to fulfill their essential macronutrient and micronutrient needs.

“We know the whole concept of yo-yo dieting. When people stop using the drug and they go off it and what happens, they get this rebound. It’s very well documented in literature that there’s a gain back. Well, they don’t gain back that same percentage of muscle lost and fat regain. They gain mostly fat back,” Baier says.

Moreover, Baier delved into the concerning issue of muscle loss during drug use, citing studies demonstrating how supplementation with myHMB® during weight loss can effectively preserve muscle mass.

For the complete interview with Shawn Baier, delve into the insights here.